MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

Adult Male 6.6 Psychological and behavioural Drug-Related Side Effects and Adverse Reactions 4-methylenedioxyamphetamine N-Methyl-3,4-methylenedioxyamphetamine Clinical Trials and Supportive Activities Immunology Medical and Health Sciences Article Stress Disorders, Post-Traumatic Substance Misuse 03 medical and health sciences 0302 clinical medicine Double-Blind Method Clinical Research Behavioral and Social Science Humans N-Methyl-3 10. No inequality Stress Disorders Depression Evaluation of treatments and therapeutic interventions Middle Aged Post-Traumatic Stress Disorder (PTSD) Anxiety Disorders Combined Modality Therapy Brain Disorders 3. Good health Mental Health Good Health and Well Being Treatment Outcome 6.1 Pharmaceuticals Post-Traumatic Mental health Female Patient Safety
DOI: 10.1176/appi.focus.23021011 Publication Date: 2023-07-14T07:05:36Z
ABSTRACT
AbstractPost-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001,d = 0.91) and to significantly decrease the SDS total score (P = 0.0116,d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was −24.4 (s.d. 11.6) in the MDMA group and −13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (39)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....